PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July31, 2017, the Board of Directors of Puma Biotechnology, Inc. (the “Company”) approved the promotion of Richard P. Bryce, MBChB, MRCGP and MFPM, from Senior Vice President, Clinical Research and Development to Chief Medical and Scientific Officer of the Company, effective August1, 2017. In connection with his promotion, Dr.Bryce’s annual base salary will increase from $413,255 to $454,580.

Item 5.02 Other Events.

On August2, 2017, the Company announced that the Committee for Medicinal Products for Human Use (the “CHMP”), the scientific committee of the European Medicines Agency, had issued its Day-180 List of Outstanding Issues in the process of their ongoing regulatory review of the Company’s Marketing Authorisation Application (“MAA”) for neratinib for the extended adjuvant treatment of HER2-positive early stage breast cancer in patients who have previously been treated with trastuzumab (Herceptin^®)-based adjuvant therapy.

The CHMP has requested additional data analyses related to the safety and efficacy of neratinib and has instituted a clock stop in order to allow the Company time to respond to this List of Outstanding Issues. The CHMP has set a deadline of December22, 2017 for the Company to respond to the list. The Company expects the CHMP to issue an opinion regarding the MAA for neratinib in the first quarter of 2018.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements, including statements regarding the expected timing with respect to the CHMP’s opinion regarding the MAA for neratinib. All forward-looking statements included in this Current Report on Form 8-K involve risks and uncertainties that could cause the Company’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the fact that the Company currently has no product revenue, the Company’s dependence upon the commercial success of NERLYNX™ (neratinib), the Company’s history of operating losses and its expectation that it will continue to incur losses for the foreseeable future, risks and uncertainties related to the Company’s ability to achieve or sustain profitability, the Company’s ability to predict its future prospects and forecast its financial performance and growth, failure to obtain sufficient capital to fund the Company’s operations, the effectiveness of sales and marketing efforts, the Company’s ability to obtain FDA approval or other regulatory approvals for others product candidates, the challenges associated with conducting and enrolling clinical trials, the risk that the results of clinical trials may not support the Company’s drug candidate claims, even if approved, the risk that physicians and patients may not accept or use the Company’s products, the Company’s reliance on third parties to conduct its clinical trials and to formulate and manufacture its drug candidates, risks pertaining to securities class action, derivative and defamation lawsuits, the Company’s dependence on licensed intellectual property, and the other risk factors disclosed in the periodic and current reports filed by the Company with the Securities and Exchange Commission from time to time, including the Company’s Annual Report on Form 10-K for the year ended December31, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.

About PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI)

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4.